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Abstract
Background: Prebiotics, probiotics and synbiotics can be used to modulate both the composition and activity of the gut
microbiota and thereby potentially affecting host health beneficially. The aim of this study was to investigate the effects of
eight synbiotic combinations on the composition and activity of human fecal microbiota using a four-stage semicontinuous
model system of the human colon.
Methods and Findings: Carbohydrates were selected by their ability to enhance growth of the probiotic bacteria
Lactobacillus acidophilus NCFM (NCFM) and Bifidobacterium animalis subsp. lactis Bl-04 (Bl-04) under laboratory conditions.
The most effective carbohydrates for each probiotic were further investigated, using the colonic model, for the ability to
support growth of the probiotic bacteria, influence the composition of the microbiota and stimulate formation of short-
chain fatty acids (SCFA).The following combinations were studied: NCFM with isomaltulose, cellobiose, raffinose and an oat
b-glucan hydrolysate (OBGH) and Bl-04 with melibiose, xylobiose, raffinose and maltotriose. All carbohydrates showed
capable of increasing levels of NCFM and Bl-04 during fermentations in the colonic model by 103–104 fold and 10–102 fold,
respectively. Also the synbiotic combinations decreased the modified ratio of Bacteroidetes/Firmicutes (calculated using
qPCR results for Bacteroides-Prevotella-Porphyromonas group, Clostridium perfringens cluster I, Clostridium coccoides -
Eubacterium rectale group and Clostridial cluster XIV) as well as significantly increasing SCFA levels, especially acetic and
butyric acid, by three to eight fold, as compared to the controls. The decreases in the modified ratio of Bacteroidetes/
Firmicutes were found to be correlated to increases in acetic and butyric acid (p = 0.04 and p= 0.03, respectively).
Conclusions: The results of this study show that all synbiotic combinations investigated are able to shift the predominant
bacteria and the production of SCFA of fecal microbiota in a model system of the human colon, thereby potentially being
able to manipulate the microbiota in a way connected to human health.
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Introduction
The concept of prebiotics was introduced by Gibson &
Roberfroid [1]. The vast majority of published studies have
focused on the effects of inulin, fructo-oligosaccharides and
galacto-oligosaccharides [2]. Prebiotics have been reported to
selectively stimulate growth of bifidobacteria, and to lesser
extent lactobacilli, both in vitro and in human trials [3–5].
Human trials have indicated stimulation of mineral uptake [6,7]
and an influence on cholesterol levels by reduction of
triacylglycerol concentrations in blood by prebiotics [8], and
animal studies suggest an effect of prebiotics on reduction of
cancer risk [9,10]. Abrams et al. (2007) reported prebiotics to
have an effect on BMI of adolescents [11]. Two studies have
assessed the effect of prebiotics on irritable bowel syndrome and
reported reduced frequency and severity of abdominal pain [12]
and reduction of flatulence, bloating, abdominal pain together
with self-reported global assessment of relief [13]. As reviewed
by Roberfroid et al. [2], several pilot studies suggest an effect of
prebiotics on inflammatory bowel disease (i.e. on disease
activity), which is supported by a larger trial reporting reduction
of inflammation in pouch mucosa in patients with pouchitis
[14]. There is however also a risk of side effects due to prebiotic
intake as reported by a study with patients with active Crohn’s
disease, where gastrointestinal symptoms (i.e. flatulence and
abdominal pain) were increased [15]. Also, no difference in
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disease activity and markers of intestinal inflammation was
reported, however, expression of IL-10 and IL-6 by intestinal
dendritic cells were shifted in a anti-inflammatory manner [15].
For probiotic bacteria, beneficial health effects have been
claimed since Metchnikoff, and have been reported in numerous
in vitro studies as reviewed recently [16]. Beneficial effects have
also been shown in human intervention studies addressing e.g.
the effect of a mixture of probiotic Lactobacillus rhamnosus and
Lactobacillus reuteri on atopic dermatitis [17] and diarrhea [18].
Probiotic strains L. rhamnosus GG and L. rhamnosus HN001 have
been reported to reduce prevalence of eczema [19,20].
Moreover the probiotic strain Bifidobacterium animalis subsp. lactis
Bi-07 has been reported to reduce the severity of atopic
dermatitis as compared to before probiotic treatment, however
no difference was observed between probiotic and placebo
treatment [21]. Perinatal exposure to L. rhamnosus GG showed a
tendency of restraining excessive weight gain during the first
years of life [22] and L. acidophilus NCFM preserved insulin
sensitivity in type 2 diabetics as compared to placebo, however
inflammatory markers and systemic inflammatory response were
unaffected [23].
Combining probiotic bacteria with prebiotics, i.e. so-called
synbiotics, to gain the health beneficial effects of both has been
suggested, and has been investigated both in vitro and in clinical
trials. The beneficial effects reported for humans include
favorable shift in cancer biomarkers in colon cancer patients
[24] and improvement of liver function in cirrhotic patients
[25]. A study reported post-natal synbiotic treatment of infants
to result in lower frequency of antibiotic treatment during trial
and respiratory infections occurred less frequent during the
follow-up period [26]. A study of the effect of synbiotics on
post-operative infections reported a lower bacterial infection rate
as well as shorter duration time of antibiotic treatment as
compared to placebo [27]. Also, certain synbiotics have been
observed to increase levels of lactobacilli and bifidobacteria
[24,28].
It is generally accepted that increases in lactobacilli and
bifidobacteria are desirable, and most known probiotics belong
to these genera [29]. However, it has been estimated that the colon
contains 500 to 1000 different bacterial species, which may be
linked to the health status of the host [30]. Recently particular
interest has been given to altered ratios of Bacteroidetes/Firmicutes.
Ratios are reported to be altered in obese [31,32] and type 2
diabetics [33]. However, other studies report no changes in
Bacteroidetes/Firmicutes ratio in obese as compared to lean subjects
[34,35]. Metabolic activity of the gut microbiota results in
production of short-chain fatty acids (SCFA), mainly acetic,
propionic and butyric acids which serve as fuel for the intestinal
epithelial cells and stimulate growth of colonic epithelial cells
[36,37]. Butyric acid and propionic acid are reported to inhibit
growth and promote apoptosis of human colonic carcinoma cell
lines [38,39], while anti-inflammatory properties have been
reported for acetic, propionic and butyric acid [40]. It was
recently demonstrated that acetic acid produced by bifidobacteria
stimulate epithelial cell defense against infection by Escherichia coli
O157:H7 [41].
Studying the complex microbial community of the human colon
presents methodological challenges but despite limitations, colonic
models are seen as useful tools for in vitro investigation of the
composition and metabolism of colonic bacteria [42]. The models
have been used to study the interaction of the opportunistic
pathogen Staphylococcus aureus and colonic microbial population
[43], survival of probiotics [44] and have been used to investigate
effects of known prebiotics on the microbial community [45] as
well as for identification of novel prebiotic candidates [46]. The
four-stage colonic model used in this study has been validated by
human trials with regard the bifidogenic effect of a synbiotic
combination of NCFM and lactitol and enhancement of SCFA by
polydextrose [3,47–50].
In the present study 37 potentially prebiotic carbohydrates were
investigated for their ability to enhance the growth of the widely
used and well studied probiotic bacteria Lactobacillus acidophilus
NCFM and Bifidobacterium animalis subsp. lactis Bl-04 [23,51–55].
Eight synbiotic combinations were selected for further analysis in
the colonic model; NCFM combined with isomaltulose, cellobiose,
raffinose or endo-1,3-b-D-glucanase hydrolyzed oat b-glucan, and
Bl-04 combined with melibiose, xylobiose, raffinose or maltotriose.
Performance in the four-stage model of the human colon
inoculated with human fecal samples was evaluated with respect
to growth stimulation of the probiotic strains by qPCR and
production of short-chain fatty acids, investigated by gas
chromatography. Moreover, to obtain quantitative information
of the effects of synbiotics on the modified ratio of Bacteroidetes/
Firmicutes, qPCR was applied for determination of microbial
numbers.
Results
Selection of Potential Prebiotic Carbohydrates for
Stimulation of Growth of L. acidophilus NCFM and B.
animalis subsp. lactis Bl-04
A library of potentially prebiotic carbohydrates (Table S1)
was investigated for the growth enhancement of NCFM and Bl-
04 (Figure S1). Although distinct differences were observed
between NCFM and Bl-04, both preferred carbohydrates with a
DP between two to five. Apart from glucose (control) and
galactose (no. 6) which stimulated growth of NCFM, the
monosaccharides included in this study did not result in growth
enhancement of neither NCFM nor Bl-04. Disaccharides such
as isomaltose (no. 10) and gentiobiose (no. 12) stimulated growth
of both NCFM and Bl-04 while cellobiose (no. 11) strongly
enhanced growth of NCFM and to some extent Bl-04.
Melibiose (no. 8) and xylobiose (no. 17) only stimulated growth
of Bl-04 and isomaltulose (no. 9) strongly enhanced growth of
NCFM but not Bl-04. Among the trisaccharides D-raffinose (no.
18) stimulated growth of both NCFM and Bl-04, panose (no.
19) stimulated growth of Bl-04, and to some extent NCFM,
while maltotriose (no. 20) highly stimulated growth of Bl-04 but
not NCFM. The tetrasaccharide stachyose (no. 21) and the
pentasaccharide verbascose (no. 22) stimulated growth of both
NCFM and Bl-04. No, or very limited, in vitro growth
enhancement was observed for carbohydrates with DP above
five. Based upon the screening the following combinations of
carbohydrates and probiotic bacteria were selected for studies in
the colonic model. Being able to support growth of both NCFM
and Bl-04, raffinose (no.18), in combinations with both bacteria,
isomaltulose (no. 9) and cellobiose (no. 11) in combination with
NCFM and melibiose (no. 8), xylobiose (no. 17) and maltotriose
(no. 20) in combination with Bl-04 were selected for evaluation
in the colonic model of the human colon. Oat b-glucan has
previously been reported to increase cecal numbers of L.
acidophilus [56], therefore oat b-glucan hydrolyzed (OBGH) by
endo-1,3-b-D-glucanase (no. 26) was included in combination
with NCFM although no growth enhancement was observed
under laboratory conditions.
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Effects of Selected Carbohydrates on Growth
Enhancement of L. acidophilus NCFM, B. animalis subsp
lactis Bl-04 in the Colonic Model System
In fermentations with NCFM, all combinations increased
NCFM numbers in the order of 102–104 fold (Table 1A) with
the levels of NCFM slightly decreasing throughout the colonic
model.
For the fermentations with Bl-04 and the selected carbohydrates
resulted in an increase of Bl-04 in the order of 102 for the
combinations with raffinose and maltotriose, and in the order of
10 for the combinations with melibiose and xylobiose (Table 1B).
Also for the synbiotic combinations with Bl-04, the numbers
decreased slightly throughout the colonic model.
For NCFM in combination with isomaltulose or cellobiose,
numbers of bifidobacteria were increased by a factor 10 and
NCFM in combination with raffinose increased bifidobacteria by a
factor 102 (data not shown). The combination of NCFM and
OBGH did not affect levels of bifidobacteria. The fermentations of
Bl-04 and raffinose interestingly, decreased levels of lactobacilli, in
the order of 10 fold, in vessels V1–V2 while the combination of Bl-
04 with melibiose decreased levels of lactobacilli in the order of
10–103 fold (data not shown). The combinations of Bl-04 and
xylobiose or maltotriose increased lactobacilli numbers in the
range of a factor 10–102.
Numbers of Lactobacillus spp. and Bifidobacterium spp. were also
determined, however numbers of NCFM and Bl-04 were higher
than that of lactobacilli and bifidobacteria, respectively. This was
however not observed for control simulations, indicating a PCR-
bias due to high levels of NCFM and Bl-04, respectively, and these
results have therefore not been included.
Effects of Selected Combinations of Carbohydrates, L.
acidophilus NCFM and B. animalis subsp. lactis Bl-04 on
the Composition of the Colonic Model System
Microbiota
Numbers of Enterobacteriaceae, Bacteroides-Prevotella-Porphyromonas
group belonging to Bacteroidetes and Faecalibacterium prausnitzii,
Clostridium perfringens cluster I, Clostridium coccoides - Eubacterium
rectale group and Clostridial cluster XIV belonging to the Firmicutes,
were assessed by qPCR, To avoid a complex description of the
changes the modified ratio Bacteroidetes/Firmicutes was used to
describe shifts in the microbial composition and the modified ratio
showed a tendency of being decreased by all synbiotic combina-
tions as seen in Figure 1. (Firmicutes was calculated using numbers
of Clostridium perfringens cluster I, Clostridium coccoides - Eubacterium
rectale group and Clostridial cluster XIV). Numbers of F. prausnitzii
were constant for all synbiotic combinations and were 10 fold
higher than the sum of the other bacteria, likely due to PCR bias,
and F. prausnitzii was therefore not included in calculations of the
modified ratio. For the combination of Bl-04 and maltotriose an
outlier in V2 was not included. The decrease in the modified ratio
was most pronounced in the first and second vessels of the model
system. For fermentations of NCFM synbiotics, all combinations
decreased modified Bacteroidetes/Firmicutes ratio in vessel V1
(p.0.05) except of the combination of NCFM with OBGH
(p= 0.05). All fermentations showed tendency to decrease the ratio
in V2, especially NCFM in combination with isomaltulose,
cellobiose and OBGH (p= 0.05 to 0.09). In the fermentations
with Bl-04, ratio showed tendency of decrease for all combina-
tions, in particular combinations of Bl-04 with melibiose, xylobiose
and raffinose in V1 (p = 0.08 to 0.09). Ratios in V2, of the colonic
model were lower for Bl-04 in combination with melibiose or
raffinose (p,0.05).
Average levels of Enterobacteriaceae were in the range of 4,6–5.0
(log10 bacteria/mL) and were not changed by the synbiotic
combinations (data not shown).
Effects of Selected Carbohydrates, L. acidophilus NCFM
and B. animalis subsp. lactis Bl-04 on Production of
Volatile Fatty Acids in the Colonic Model System
The concentrations of short-chain fatty acids (SCFA) and
branched-chain fatty acids (BCFA) produced during the fermen-
tations in the colonic model are presented in Figure 2 and Figure
S2.
All combinations increased the amount of both acetic and
butyric acid by three to eight times as compared to levels in the
Table 1. Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bl-04 numbers (log10 bacteria/mL 6 SE)
detected by quantitative PCR for colonic fermentations with A) NCFM and carbohydrates stated and B) Bl-04 and carbohydrates
stated (n = 2 for all except Bl-04 and maltotriose and control fermentations where n= 3).
A control
NCFM+
isomaltulose NCFM+ cellobiose NCFM+ raffinose NCFM+ OBGH1
L. acidophilus NCFM V1 4.14 (60.65) 7.65 (60.21)* 7.57 (60.01)* 7.58 (60.28)* 7.51 (60.19)*
V2 4.19 (60.32) 7.10 (60.03)* 7.52 (60.01)** 7.37 (60.46)* 6.94 (60.29)*
V3 3.23 (60.33) 6.70 (60.08)** 7.21 (60.06)** 7.01 (60.25)** 6.19 (60.30)*
V4 3.06 (60.16) 6.38 (60.19)** 6.65 (60.05)** 6.63 (60.31)** 5.01 (60.64)*
B control Bl-04+ melibiose Bl-04+ xylobiose Bl-04+ raffinose Bl-04+ maltotriose2
B. animalis subsp. lactis Bl-04 4.84 (60.22) 6.25 (60.35)* 6.30 (60.50) 7.10 (60.14)* 6.91 (60.33)*
4.76 (60.27) 6.01 (60.24)* 6.48 (60.45)* 7.18 (60.15)* 7.13 (60.30)**
4.39 (60.32) 5.44 (60.28) 5.92 (60.49) 6.48 (60.21)* 6.70 (60.28)**
4.25 (60.39) 4.96 (60.48) 5.46 (60.56) 5.92 (60.21)* 6.08 (60.02)*
*p,0.05.
**p,0.005.
1Oat b-glucan hydrolysate.
2Maltotriose from Sigma-Aldrich.
doi:10.1371/journal.pone.0047212.t001
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control fermentations (Figure 2A and 2C) while levels of propionic
acid were less increased (Figure 2B). For synbiotic fermentations,
concentrations of acetic and butyric acid showed a tendency to
decrease in vessels V3 and V4 as compared to V1 and V2,
corresponding to the decreased saccharolytic activity reported
from the ascending and transverse to the descending and sigmoid
regions of the human colon [2]. Interestingly, there was a negative
correlation between the modified ratio of Bacteroidetes/Firmicutes
and concentrations of acetic and butyric acids, respectively, for
both NCFM and Bl-04 synbiotics as seen from Figures 3A and 3B,
respectively. No correlation of modified Bacteroidetes/Firmicutes ratio
and concentration of propionic acid was observed.
In the NCFM fermentations, the stimulation of acetic acid
production was strongest for isomaltulose followed by raffinose,
OBGH and cellobiose, whereas in the Bl-04 fermentations the
strongest induction of acetic acid was observed with raffinose,
followed by xylobiose, melibiose and maltotriose. The strongest
butyric acid inducer in the NCFM fermentations was raffinose
followed by cellobiose, isomaltulose and OBGH, and in the Bl-04
fermentations melibiose followed by xylobiose, raffinose and
maltotriose. Propionic acid production in NCFM fermentations
was stimulated by all combinations except for NCFM in
combination with raffinose (Figure 2B). For fermentations with
Bl-04 synbiotics, all combinations but Bl-04 in combination with
maltotriose showed a tendency of increasing levels of propionic
acid.
No major alterations between the synbiotic treatments with
regard to total levels of SCFA produced were observed. Total
SCFA levels ranged between 532.9671.2 and 693.2635.2 mM
for NCFM fermentations, and 553.3657.4 and 631.4657.9 mM
for Bl-04 fermentations, demonstrating a four to five fold increase
compared to SCFA in control fermentations (results not shown).
Significant reductions in concentrations of 2-methylbutyric,
isovaleric and isobutyric acids, products of protein fermentation
[57] were observed for all synbiotic combinations as compared to
the controls (Figure S2) and no differences were observed between
treatments. Concentrations of BCFA were lowest in vessel V1 and
tended to rise throughout vessels V2 to V4 matching the increased
proteolytic activity observed from the ascending colon toward the
sigmoid colon [57].
Discussion
In the past decades there has been increasing focus on the key
role the gut microbiota appears to play in host health and disease.
Further, probiotics, prebiotics and synbiotics can be used to
modulate both composition and activity of the gut microbiota in a
way beneficial to the human host [2,16]. Traditionally increases in
lactobacilli and bifidobacteria have been seen as particularly
beneficial [29]. Recently, the ratios between Bacteroidetes and
Firmicutes has become of special interest as it may be linked to so-
called life style diseases such as obesity and type 2 diabetes [31,33].
An important activity of the gut microbiota is formation of
short-chain fatty acids (SCFA) [2]. SCFA contribute to human
health by acting as an energy source for intestinal epithelial cells,
and especially butyric acid has received much attention with
reports indicating a range of functions ranging from anticarcino-
genic to anti-inflammatory effects [38–40]. SCFA are able to
inhibit pathogenic growth by lowering pH in the intestinal lumen
[2] and acetic acid, produced by bifidobacteria, has been reported
to improve defense of epithelial cells towards infection by
pathogenic Escherichia coli O157:H7 [41]. For synbiotics, studies
of their effects on the intestinal microbiota and its metabolic
activity are limited and so far, rarely based upon combinations of
well studied probiotics and prebiotics screened for actually
stimulating growth of the particular probiotics as is the case in
the present study.
For selection of growth promoting properties, a library
consisting of 37 carbohydrates, with a wide range of different
degrees of polymerization, glycosidic linkages and monomeric
structures, was screened under laboratory conditions for their
ability to stimulate growth of the well studied probiotic bacteria
Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp.
lactis Bl-04 [23,51–55]. As expected, clear differences were
observed between the carbohydrates. Further, the results are in
line with previous studies with regard to stimulation of growth of
Bl-04 and not NCFM by xylobiose and the lack of growth
stimulation of both NCFM and Bl-04 by pullulan. But results differ
from earlier findings in relation to growth of NCFM on
polydextrose or panose and Bl-04 on gentiobiose [58]. The
highest growth stimulation for both NCFM and Bl-04 was
observed for carbohydrates with DP of two to five. To our
knowledge, only the potential of xylobiose, gentiobiose, panose
and pullulan in stimulating growth of NCFM and Bl-04 has
previously been reported [46,58]. The prebiotic potential of the
remaining carbohydrates from the present study are, to our
knowledge, for the first time investigated with respect to growth
stimulation of NCFM and Bl-04.
The carbohydrates stimulating growth under laboratory condi-
tions also were able to stimulate growth of the two probiotics in the
colonic model system. Also oat b-glucan hydrolyzed by endo-1,3-
b-D-glucanase (OBGH), which did not support growth of NCFM
under laboratory conditions, was able to support growth of NCFM
in the colonic model. The effect of OBGH in the simulated colonic
conditions demonstrates the limitations of pure culture screenings,
and suggests that in the presence of complex microbiota, the
prebiotic effects of more complex carbohydrates are possibly
enhanced, as compared to pure culture fermentations. It was
observed, for all selected carbohydrates, that levels of NCFM and
Bl-04 in the colonic model were higher than those of total
lactobacilli and bifidobacteria, respectively. However, this was not
observed in control fermentations and is most likely explained by a
PCR bias caused by a high ratio of NCFM and Bl-04 as compared
to other lactobacilli and bifidobacteria. Increase in cell numbers
for a probiotic in the gastrointestinal tract is seen as a competitive
advantage. In this regard the strongest effect of the carbohydrates
tested was seen for NCFM; the levels of this probiotic were
increased by 102 to 104 fold by all carbohydrates selected i.e.
isomaltulose, cellobiose, raffinose and OBGH (Table 1A). The
potential competitive advantage offered to Bl-04 by the carbohy-
drates tested was of smaller magnitude, amounting to 10 to 102fold
increases in the Bl-04 numbers. The results obtained indicate that
specific prebiotics can be selected to provide a competitive
Figure 1. Ratios of Bacteroidetes/Firmicutes as determined by qPCR. Ratios of Bacteroidetes/Firmicutes (Bacteroides-Prevotella-Porphyromonas
group/Clostridium perfringens cluster I, Clostridium coccoides - Eubacterium rectale group and Clostridial cluster XIV) for fermentations with
Lactobacillus acidophilus NCFM (A) in combination with isomaltulose (N) (n = 2), cellobiose (m)(n = 2), raffinose (¤)(n = 2) and OBGH (&)(n = 2);
Bifidobacterium animalis subsp. lactis Bl-04 (B) in combination with melibiose (#)(n = 2), xylobiose (D) (n = 2), raffinose (e)(n = 2) and maltotriose
(%)(n = 3). Control fermentations (n = 3) are denoted by crosses and dotted lines and results are shown as mean values for each vessel, V1–V4, 6
standard error of mean. *p,0.05.
doi:10.1371/journal.pone.0047212.g001
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Figure 2. Concentrations of short-chain fatty acids as determined by gas chromatography; acetic acid (A), propionic acid (B) and
butyric acid (C) in vessels V1–V4 of the colonic model after control and synbiotic fermentations. Synbiotic fermentations are denoted as
Synbiotics, Gut Microbiota and Fatty Acids
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e47212
follows: Lactobacillus acidophilus NCFM in combination with; isomaltulose (N)(n = 2), cellobiose (m)(n = 2), raffinose (¤)(n = 2) and OBGH (&)(n = 2)
and Bifidobacterium animalis subsp. lactis Bl-04 in combination with; melibiose (#)(n = 2), xylobiose (D) (n = 2), raffinose (e)(n = 2) and maltotriose
(%)(n = 3). Control fermentations (n = 3) are denoted by crosses and dotted lines and results are shown as mean concentrations (mmol/L) for each
vessel 6 standard error of mean. *p,0.05, **p,0.005.
doi:10.1371/journal.pone.0047212.g002
Figure 3. Correlation between Bacteroidetes/Firmicutes ratios and concentrations of SCFA. Correlation between concentrations of acetic
acid (#) and butyric acid (%) and Bacteroidetes/Firmicutes ratios (Bacteroides-Prevotella-Porphyromonas group/Clostridium perfringens cluster I,
Clostridium coccoides - Eubacterium rectale group and Clostridial cluster XIV) for synbiotic combinations with Lactobacillus acidophilus NCFM (A) and
Bifidobacterium animalis subsp. lactis Bl-04 (B). Concentrations of acetic and butyric acid in control fermentations are denoted by grey circles and
squares, respectively. The Spearman Rank probabilities (p) and correlations (R) are shown in the graphs.
doi:10.1371/journal.pone.0047212.g003
Synbiotics, Gut Microbiota and Fatty Acids
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advantage for a probiotic Lactobacillus species, probiotic Bifidobac-
terium species or both in a colonic model system.
Stimulation of SCFA by synbiotics including any of the
candidate prebiotics used in the present study is to our knowledge
only reported for raffinose in rats [59]. In in vitro studies only
comprising prebiotics, i.e. melibiose, isomaltulose, cellobiose,
xylobiose, maltotriose, raffinose and oat b-glucans, increases in
acetic acid were reported to be between two and six times higher
as compared to controls and for butyric acid the highest
concentrations observed were four times higher as compared to
control [60–64]. These increases in concentrations of acetic and
butyric acids are, however, lower than the increases observed for
all synbiotic combinations investigated in the present study where
concentrations were three to eight times higher for both acetic and
butyric acids as compared to control, The findings emphasize that
a synergistic effect may be obtained when combining these
prebiotic candidates with the probiotic strains NCFM and Bl-04.
NCFM is a homofermentative Lactobacillus strain which does not
produce acetic acid and presence of NCFM alone does not
increase production of acetic acid by the microbiota of this colonic
model system [50]. Bifidobacteria produce acetic acid and
increases of acetic acid in the colonic model are reported for
another probiotic, B. animalis subsp. lactis Bi-07 [65]. Interestingly,
the present study found that combinations of NCFM with
carbohydrate stimulated production of acetic acid to the same
extent as observed for Bl-04 in combination with carbohydrates
(Figure 2A). We know of no previous studies reporting this and the
present observation indicates that synbiotic combinations with
NCFM and synbiotic combinations with Bl-04 may induce the
same shift in metabolic activity of the microbiota and thereby
potentially have the same SCFA mediated health benefits.
A shift in the modified ratio of Bacteroidetes/Firmicutes was seen in
the presence of the eight different synbiotic combinations selected
(Figure 1). To our knowledge the combined effect of probiotics and
prebiotics on the ratio of Bacteroidetes/Firmicutes has not been
previously reported. Regarding the effect of probiotics on the
Bacteroidetes/Firmicutes ratio, only one published study seems to
exist. This study, on children with atopic dermatitis and healthy
controls, did not report effects for NCFM or B. animalis subsp. lactis
Bi-07 on the ratio of Bacteroidetes/Firmicutes [52]. We are not aware
of any previous studies reporting that prebiotics induce a shift in
this ratio. The decrease in the modified ratio of Bacteroidetes/
Firmicutes observed in the present study, was moreover found to be
correlated to increases in concentrations of both acetic and butyric
acid (Figure 3). Although shifts in Bacteroidetes/Firmicutes ratios have
previously been reported to be associated with changes in acetic
and butyric acids [32], direct correlations have to our knowledge
not been reported previously. In the present study the donors were
healthy lean subjects, and the findings cannot directly be
compared to human studies. However, the ratios of modifed
Bacteroidetes/Firmicutes observed in the presence of the selected
synbiotic combinations varied between 0.002 and 0.9 (0.3–1.1 for
control fermentations), and this variation is within the range of
what has previously been reported for healthy humans, humans
with diabetes type 2 and obese humans [31–33]. Although no
conclusive link between the ratio of Bacteroidetes/Firmicutes and
health status has been established, our results indicate that the
synbiotic combinations investigated in the present study may be
able to manipulate the composition of the microbiota, i.e. the
modified ratio of Bacteroidetes/Firmicutes, in a way which could be
important to human health.
Several potential prebiotics capable of stimulating the growth of
NCFM and Bl-04 under laboratory conditions were identified, and
the most interesting combinations were, in combination with the
two probiotic strains, selected for further analysis in a human
colonic model system. The selected combinations showed potential
as synbiotics as they were able to support growth of the probiotic
bacteria, affect the microbial composition, observed by a shift in
the modified ratio of Bacteroidetes/Firmicutes, and shift the metabolic
activity levels of the microbiota, demonstrated by an increase in
concentrations of SCFA. The effects of the synbiotics on
composition and activity of the microbiota remain to be confirmed
by human trials.
Materials and Methods
Screening of Carbohydrates for Stimulation of Growth of
L. acidophilus NCFM and B. animalis subsp. lactis Bl-04
Carbohydrates used in screening experiments are listed in Table
S1. For the non-commercial carbohydrates prepared for this study
(no. 20, 23–30), the degree of polymerization (DP) was determined
by High Performance Anion Exchange Chromatography
(HPAEC) chain profiling [66], except for oat b-glucan for which
size exclusion chromatography was applied [67]. The library
included carbohydrates with a large range of DP and a number of
different monomeric units and glycosidic linkages (Table 2).
Screening was performed essentially as described previously
[58]. Briefly, cultures of L. acidophilus NCFM and B. animalis subsp.
lactis Bl-04 were pre-cultivated from stocks stored at 270uC,
anaerobically for 24 h at 37uC in MRS broth (Lab M, Bury,
United Kingdom). Anaerobic conditions were generated by the
Hungate boiling system [68]. Modified MRS (without glucose)
containing 1% (w/v) carbohydrate was inoculated with cell-
suspensions of NCFM and Bl-04 (1% v/v). Modified MRS with no
carbohydrate was used as control. Growth for 24 h at 37uC was
monitored by optical density at 600 nm using a BioscreenH C
instrument (Labsystems, Helsinki, Finland) placed inside an
anaerobic hood (80% N2, 10% CO2 and 10% H2). The area
under the growth curves during 24 h was used to quantify growth
[58]. Determinations were performed in two separate sets of
experiments each in quadruplicate. Polydextrose (PDX;Danisco
Sweetners, Redhill, UK), previously shown to have prebiotic
effects [3,49,58] and glucose (Serva, Germany) were included for
comparison.
Four-stage Model of the Human Colon
Fermentations were performed in a four-stage semi-continuous
model of the human colon (EnteroMixH, Danisco,) [49]. Shortly,
the colonic model consists of four parallel units, each unit
consisting of four vessels (V1–V4), connected sequentially and
representing the different parts of the colon; ascending- (V1),
transverse- (V2), descending colon (V3) and the sigmoid/rectum
area (V4), respectively. Volumes were 6, 8, 10 and 12 mL,
respectively, and pH was set at 5.5, 6.0, 6.5 and 7.0, respectively,
and adjusted using gaseous ammonia in oxygen-free N2 gas.
Fermentations were performed under thermostatic conditions
(37uC). Faecal samples were obtained with verbal consent from
healthy human volunteers (n = 3) and samples were precondi-
tioned and incubated 24 hrs before use as previously described
[49]. Faeces from one volunteer was used to run a set of four
parallel fermentations. As faecal samples were anonymous and no
medical or register was kept for the donors, there is according to
national regulations no need for approval from the ethics
committee nor is written consent demanded.
Candidate prebiotics were added (2% w/v) to synthetic ileal
fluid [49,69], used as basic medium, together with NCFM
(lyophilized) or Bl-04 (oxygen-free 0.9% NaCl, as described above)
at a rate of 26107 cells/mL (determined by flow cytometry (FACS
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Calibur-system; BD Biosciences, San Jose, CA, USA; as described
by [70]). For control fermentations neither candidate prebiotic nor
probiotic bacteria were added to the medium and fermentations
were performed in quadruples, with one unit of the colonic model
for the control and the remaining units for the synbiotic
treatments. Fermentations were performed as independent dupli-
cate runs for the synbiotic combinations whilst controls and the
combination of Bl-04 and maltotriose were done in triplicate.
Operation of the model system was done as described previously
[49] and fermentations were carried out for 48 h after which the
content of each vessel was collected for further analysis. Bacteria
from each vessel were harvested by centrifugation (48,0006g,
15 min, 20uC). The harvested bacteria and supernatant were
stored at 270uC until DNA extraction and volatile fatty acid
analysis.
Determination of Microbial Numbers by Quantitative
Real-time Polymerase Chain Reaction (qPCR)
DNA was extracted and purified (QIAampH DNA Stool Mini
Kit, Qiagen, Germany) according to manufacturer’s instructions
with the following exceptions: an additional step of bead beating
(45 s, 6.0 m/s in FastPrep H FP120 instrument, Bio101 Savant
Instruments, Inc. Holbrook, NY) with 1 g 1,000 mm glass beads
(Sigma-Aldrich) was included prior to extraction, and lysis of
bacterial cells was performed at 95uC instead of 70uC for 10 min.
Using specific primers and probes, and TaqmanH or SYBR
green methodology (Applied Biosystems, Warrington, USA) total
densities of different bacteria were determined by qPCR. Target
groups, methodology, annealing temperature, bacteria for stan-
dard curves and references are listed in Table 2. Assays were
performed with ABI PrismH 7000 or 7500 FAST sequence
Detection System (Applied Biosystems). Quantification was done
using standard curves made by 10 fold dilutions series of target
species DNA.
Volatile Fatty Acid Analysis
Concentrations of short-chain fatty acids (SCFA), acetic,
propionic, lactic and butyric acids, and branched-chain fatty acids
(BCFA), 2-methylbutyric, isovaleric and isobutyric acid, using gas
chromatography as described by Holben et al. (2002) [71].
Statistical Analysis
The data of from the pure culture growth experiments are
reported as the area under the growth curves, bacterial
enumeration are expressed as log10 microbes/mL (6SE) and
concentrations of volatile fatty acids in mM (6SE).
Data from control and synbiotic fermentations was compared
by one-way ANOVA using Statistics Online Computational
Resource (http://www.socr.ucla.edu/SOCR.html) and correla-
tion between Bacteroidetes/Firmicutes and SCFA was computed by
Spearman Rank correlation using Free Statistics Software (Office
for Research and Development and Education, version 1.1.23-r7.
http://www.wessa.net). P-values below 0.05 were considered
significant.
Supporting Information
Figure S1 Growth of Lactobacillus acidophilus NCFM
(dark grey) and Bifidobacterium animalis subsp. lactis
Bl-04 (white) shown as area under the growth curve.
Carbohydrates are numbered 1–37 according to Table S1 and
listed according to degree of polymerization (DP). The growth of
Bl-04 on carbohydrates 4, 34 and 37 was not tested. Glucose and
polydextrose (PDX) were included for comparison and results are
shown as mean values 6 standard error of mean (n= 8).
(TIF)
Figure S2 Concentrations of branched-chain fatty acids
as determined by gas chromatography; isobutyric acid
(A), 2-methylbutyric acid (B) and isovaleric acid (C) in
vessels V1–V4 of the colonic model after control and
synbiotic fermentations. Synbiotic fermentations are denoted
as follows: Lactobacillus acidophilus NCFM in combination with;
Table 2. Primers, mastermixes, standard al strains and annealing temperatures used in quantitative PCR detection of target
bacteria.
Target bacteria Primer Standard bacterium
Annealing
temp. (6C) Reference
Lactobacillus acidophilus NCFM NCFM_F NCFM_R NCFMprobe Lactobacillus acidophilus NCFM 61 [53,55] (modified)
Bifidobacterium animalis subsp.
lactis
Blact_1 Blact5 Bifidobacterium animalis subsp.
lactis (HN019)
65 [64]; [72]
Lactobacillus spp. Lab-0677 Lac1 Lactobacillus acidophilus
(ATCC 43121)
56 [73]; [74]
Bifidobacterium spp. BF BGR Bprobe Bifidobacterium adolescentis (DSM
20083)
60 [49]
Bacteroides-Prevotella-
Porphyromonas group
gBacter_F gBacter_R Bacteroides fragilis (ATCC 25285) 64 [75]
Clostridium perfringes cluster I g_Cperf_F g_Cperf_R Clostridium perfringes (ATCC
13124)
55 [75]
Clostridium coccoides -
Eubacterium. rectale group
g_Ccoc_F g_Ccoc_R Rumincoccus productus (DSM 2050 61 [75]
Clostridial cluster XIV CXIV F1 CXIV R2 Clostridium bolteae (DSM 15670) 52 [76]
Faecalibacterium prausnitzii Fpraus_F Fpraus_R Faecalibacterium prausnitzii (ATCC
27768)
62 [75]
Enterobacteriaceae En-lsu3F En-lsu3’R Escherichia coli (11775) 62 [77]
doi:10.1371/journal.pone.0047212.t002
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isomaltulose (N)(n = 2), cellobiose (m)(n = 2), raffinose (¤)(n = 2)
and OBGH (&)(n = 2) and Bifidobacterium animalis subsp. lactis Bl-04
in combination with; melibiose (#)(n = 2), xylobiose (D) (n = 2),
raffinose (e)(n = 2) and maltotriose (%)(n = 3). Control fermenta-
tions (n = 3) are denoted by crosses and dotted lines and results are
shown as mean concentrations (mmol/L) for each vessel 6
standard error of mean. *p,0.05, **p,0.005
(TIF)
Table S1 Carbohydrates screened for growth stimula-
tion of Lactobacillus acidophilus NCFM and Bifidobac-
terium animalis subsp. lactis Bl-04 listed with names
and manufacturers. Size is given as degree of polymerization
(DP).
(DOC)
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